Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism
Open Access
- 14 July 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 29 (10) , 1092-1105
Abstract
Antidepressants often disrupt sleep. Vortioxetine, a multimodal antidepressant acting through serotonin (5-HT) transporter (SERT) inhibition, 5-HT3, 5-HT7and 5-HT1Dreceptor antagonism, 5-HT1Breceptor partial agonism, and 5-HT1Areceptor agonism, had fewer incidences of sleep-related adverse events reported in depressed patients. In the accompanying paper a polysomnographic electroencephalography (sleep-EEG) study of vortioxetine and paroxetine in healthy subjects indicated that at low/intermediate levels of SERT occupancy, vortioxetine affected rapid eye movement (REM) sleep differently than paroxetine. Here we investigated clinically meaningful doses (80–90% SERT occupancy) of vortioxetine and paroxetine on sleep-EEG in rats to further elucidate the serotoninergic receptor mechanisms mediating this difference. Cortical EEG, electromyography (EMG), and locomotion were recorded telemetrically for 10 days, following an acute dose, from rats receiving vortioxetine-infused chow or paroxetine-infused water and respective controls. Sleep stages were manually scored into active wake, quiet wake, and non-REM or REM sleep. Acute paroxetine or vortioxetine delayed REM onset latency (ROL) and decreased REM episodes. After repeated administration, vortioxetine yielded normal sleep-wake rhythms while paroxetine continued to suppress REM. Paroxetine, unlike vortioxetine, increased transitions from non-REM to wake, suggesting fragmented sleep. Next, we investigated the role of 5-HT3receptors in eliciting these differences. The 5-HT3receptor antagonist ondansetron significantly reduced paroxetine’s acute effects on ROL, while the 5-HT3receptor agonist SR57227A significantly increased vortioxetine’s acute effect on ROL. Overall, our data are consistent with the clinical findings that vortioxetine impacts REM sleep differently than paroxetine, and suggests a role for 5-HT3receptor antagonism in mitigating these differences.Keywords
This publication has 108 references indexed in Scilit:
- Can pharmaco-electroencephalography help improve survival of central nervous system drugs in early clinical development?Drug Discovery Today, 2014
- The relationship between obesity and health-related quality of life in Chinese patients with schizophreniaInternational Journal of Psychiatry in Clinical Practice, 2012
- Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatmentJournal of Neural Transmission, 2012
- Predator stress engages corticotropin-releasing factor and opioid systems to alter the operating mode of locus coeruleus norepinephrine neuronsNeuropharmacology, 2012
- Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy SubjectsBasic & Clinical Pharmacology & Toxicology, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatmentJournal of Neural Transmission, 2010
- Neurobiological mechanisms for the regulation of mammalian sleep–wake behavior: Reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidenceNeuroscience & Biobehavioral Reviews, 2007
- Antidepressants and SleepDrugs, 2005
- Effects of the selective 5‐HT1Bagonist, CGS 12066B, on sleep/waking stages and EEG power spectrum in ratsJournal of Sleep Research, 1994